Compare Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion NASDAQ 100 Equal Weighted Index Shares vs Sanofi SA — how do they compare? Direxion NASDAQ 100 Equal Weighted Index Shares trades at $121.92 (market cap $1.45B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 65.6× Direxion NASDAQ 100 Equal Weighted Index Shares's market cap, and Sanofi SA pays a 6.01% dividend while Direxion NASDAQ 100 Equal Weighted Index Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Direxion NASDAQ 100 Equal Weighted Index Shares for 48 Days and Sanofi SA for 94 Days on average.
| QQQE | SNY | |
|---|---|---|
Market Cap | $1.45B | $95.18B |
Volume | 323,568 | 2,995,646 |
Sector | Broad Market / Factor | Health |
52-Week High | $124.69 | $52.34 |
52-Week Low | $96.06 | $39.51 |
Typical Hold Time | 48 Days | 94 Days |
Enterprise Value | — | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQE, the Direxion NASDAQ-100 Equal Weighted Index ETF, trades at $121.03, down 0.71% on the day. The technical outlook is bullish based on moving averages, with oscillators neutral. Recent news highlights its equal-weight strategy reducing technology concentration compared to market-cap weighted peers. The fund provides diversified exposure to large-cap growth stocks within the Nasdaq-100 index.
The outlook for QQQE is supported by its tactical appeal as an equal-weight alternative, though it carries risks tied to Nasdaq performance and sector concentration. Investor sentiment appears cautiously optimistic given recent favorable coverage comparing it to QQQ. The absence of traditional valuation ratios is typical for an ETF tracking an index.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
